{
    "clinical_study": {
        "@rank": "163072", 
        "arm_group": {
            "arm_group_label": "Ferriprox", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the pharmacokinetics of deferiprone and its\n      3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in\n      patients with sickle cell disease."
        }, 
        "brief_title": "Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox\u00ae in Patients With Sickle Cell Disease", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Sickle Cell Disease", 
        "condition_browse": {
            "mesh_term": "Anemia, Sickle Cell"
        }, 
        "detailed_description": {
            "textblock": "This is a single-arm, single-dose study of Ferriprox in patients with sickle cell disease.\n      Patients found to be eligible will visit the clinic the day before receiving the drug, in\n      order to reconfirm eligibility and to undergo baseline assessments, and will receive a\n      single dose of 1500 mg Ferriprox under fasting conditions.  Blood and urine samples for\n      pharmacokinetic assessment will be collected over a 10-hour period. Standard safety\n      assessments will be performed throughout the study, and patients will return for a safety\n      follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, 18-45 years of age (inclusive)\n\n          2. Diagnosis of sickle cell disease, confirmed by Hb electrophoresis\n\n          3. Body weight \u2265 50 kg\n\n          4. Body mass index (BMI) \u2265 18 and \u2264 32 kg/m^2\n\n          5. Absolute neutrophil count (ANC) of >1.5 x 10^9/L\n\n          6. Women of childbearing potential must agree to either be sexually inactive or use an\n             acceptable method of birth control for 14 days prior to dosing and for 30 days\n             afterwards\n\n          7. A fertile heterosexual male must agree that he or his partner will use an effective\n             method of contraception for 14 days prior to dosing and for 30 days afterwards\n\n        Exclusion Criteria:\n\n          1. History or presence of hypersensitivity or idiosyncratic reaction to Ferriprox\n\n          2. Use of Ferriprox within the past 3 months\n\n          3. History of malignancy\n\n          4. Evidence of abnormal liver function (serum ALT level > 5 times upper limit of normal\n             or creatinine levels >2 times upper limit of normal)\n\n          5. A serious, unstable illness, as judged by the Investigator, within the past 3 months\n             before screening visit including but not limited to hepatic, renal,\n             gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or\n             immunologic disease\n\n          6. Hemodialysis during the week prior to dosing or planned for the day of dosing\n\n          7. Known difficulty in providing blood samples\n\n          8. Disorders or surgery of the gastrointestinal tract that may interfere with drug\n             absorption or may otherwise influence the PK results (e.g., resection of the small or\n             large intestine, febrile conditions, chronic diarrhea, chronic vomiting, endocrine\n             disease, severe infections, acute inflammations, etc.)\n\n          9. Clinically significant abnormalities on 12-lead ECG (e.g., QTcF \u2265 430 ms in males or\n             \u2265 450 ms in females)\n\n         10. Use of tobacco/nicotine-containing products for at least 3 months prior to study drug\n             administration\n\n         11. Use of any drugs within the past 14 days that are metabolized by the UGT1A6 enzyme\n             and hence could affect the PK of Ferriprox\n\n         12. Treatment with an investigational drug within the past 30 days or 5 half-lives of\n             that drug (whichever is longer) prior to study drug administration\n\n         13. Pregnant or nursing female"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835496", 
            "org_study_id": "LA41-0412"
        }, 
        "intervention": {
            "arm_group_label": "Ferriprox", 
            "intervention_name": "single 1500 mg dose of Ferriprox", 
            "intervention_type": "Drug", 
            "other_name": "deferiprone"
        }, 
        "intervention_browse": {
            "mesh_term": "Deferiprone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "sickle cell disease", 
            "iron overload", 
            "pharmacokinetics", 
            "Ferriprox", 
            "deferiprone"
        ], 
        "lastchanged_date": "April 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "H2L 4M1"
                }, 
                "name": "CHUM-H\u00f4pital Notre-Dame"
            }, 
            "investigator": {
                "last_name": "Denis Soulieres, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Pharmacokinetic Profile of a Single Dose of Ferriprox\u00ae in Patients With Sickle Cell Disease", 
        "overall_contact": {
            "email": "cfradette@apopharma.com", 
            "last_name": "Caroline Fradette, PhD", 
            "phone": "416-401-7543"
        }, 
        "overall_contact_backup": {
            "email": "ftricta@apopharma.com", 
            "last_name": "Fernando Tricta, MD", 
            "phone": "416-401-7332"
        }, 
        "overall_official": {
            "affiliation": "CHUM - H\u00f4pital Notre-Dame", 
            "last_name": "Denis Soulieres, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the curve, calculated over 10 hours", 
                "measure": "AUC of deferiprone and its 3-O-glucuronide metabolite", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at specified intervals up to 10 hours post-dose; urine collected from -2 to 0 hours pre-dose and at specified intervals up to 10 hours post-dose"
            }, 
            {
                "description": "Maximum measured serum concentration, calculated over 10 hours", 
                "measure": "Cmax of deferiprone and its 3-O-glucuronide metabolite", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at specified intervals up to 10 hours post-dose; urine collected from -2 to 0 hours pre-dose and at specified intervals up to 10 hours post-dose"
            }, 
            {
                "description": "Apparent terminal elimination half-life, calculated over 10 hours", 
                "measure": "T 1/2 of deferiprone and its 3-O-glucuronide metabolite", 
                "safety_issue": "No", 
                "time_frame": "Blood samples taken pre-dose and at specified intervals up to 10 hours post-dose; urine collected from -2 to 0 hours pre-dose and at specified intervals up to 10 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835496"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 (Dosing) to Day 7 (Follow-up)"
            }, 
            {
                "measure": "Frequency of serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 (Dosing) to Day 7 (Follow-up)"
            }
        ], 
        "source": "ApoPharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ApoPharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}